424 results on '"Langbaum, Jessica B."'
Search Results
2. The politics of mask-wearing: Political preferences, reactance, and conflict aversion during COVID
3. A chance to prevent Alzheimer's disease sooner than you think
4. APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts.
5. Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes
6. Informed consent process experience in Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease Colombia trial
7. Contraception in Female Volunteer in Alzheimer’s Prevention Initiative Autosomal‐dominant Alzheimer’s disease Colombia Trial, a Phase II Clinical Trial to Test Safety and Efficacy of Crenezumab
8. Statistical innovations in the API ADAD Colombia trial: a randomized, double‐blind, placebo‐controlled, parallel‐group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab
9. The Alzheimer’s Prevention Registry: A Large Internet-Based Participant Recruitment Registry to Accelerate Referrals to Alzheimer’s-Focused Studies
10. Homozygosity of the autosomal dominant Alzheimer disease presenilin 1 E280A mutation
11. GeneMatch: A novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies
12. Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
13. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease
14. Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes.
15. Tracking COVID-19 vaccination expectancies and vaccination refusal in the United States.
16. Psychological Status of the Participants in Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease Colombia
17. Real-world Site Experiences With GeneMatch: The Role of a Recruitment-related Registry in the Context of Local Site Effort to Support Alzheimer Disease Prevention Research
18. Measuring cognition and function in the preclinical stage of Alzheimer's disease
19. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort
20. 'I feel it in my gut:' Epistemic motivations, political beliefs, and misperceptions of COVID-19 and the 2020 U.S. presidential election
21. How intention to join an Alzheimer's participant recruitment registry differs by race, ethnicity, sex, and family history: Results from a national survey of US adults
22. The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease
23. Tracking COVID-19 vaccination expectancies and vaccination refusal in the United States
24. Additional file 1 of Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease
25. Reproductive health data and its relationship to baseline brain imaging and cognitive measurements in cognitively unimpaired female PSEN1 E280A mutation carriers and non‐carriers from the API ADAD Trial
26. API ADAD Colombia Trial initial findings: a randomized, double‐blind, placebo‐controlled, parallel‐ group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab
27. Clinical Profiles of Persons Who Progress to Cognitive Impairment in the Alzheimer’s Prevention Initiative (API) ADAD Colombia Trial
28. Effect of APOE4 on Plasma Phospho‐tau 217 and Neurofilament Light in the PSEN1 E280A Autosomal Dominant Alzheimer’s Disease Colombian Kindred
29. Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease
30. A Public Resource of Baseline Data from the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease Trial
31. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease
32. Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease
33. An Elicitation Study to Understand Black, Hispanic, and Male Older Adults’ Willingness to Participate in Alzheimer’s Disease-Focused Research Registries
34. Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials
35. Subjective memory complaints in preclinical autosomal dominant Alzheimer disease
36. Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials.
37. Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease.
38. Fibrillar Amyloid-β Burden in Cognitively Normal People at 3 Levels of Genetic Risk for Alzheimer's Disease
39. What words and concepts do people enrolled in research registries use to describe them?
40. Mixed methods used in the refinement of an Alzheimer’s study registry to optimize recruitment of Latinx and Black individuals
41. Psychological status in the participants of the API ADAD Colombia trial assisted by a comprehensive mental health program during COVID 19 pandemic
42. API generation program: Active immunotherapy CAD106 slows amyloid deposition in cognitively unimpaired APOE4 homozygotes
43. Psychosocial Determinants of COVID-19 Vaccination Intention Among White, Black, and Hispanic Adults in the US
44. Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease: A Retrospective Cohort Study
45. OPINION: CAP — advancing the evaluation of preclinical Alzheimer disease treatments
46. Sex differences in cognitive resilience in preclinical autosomal‐dominant Alzheimer's disease carriers and non‐carriers: Baseline findings from the API ADAD Colombia Trial.
47. Sex Differences in Cognitive Abilities Among Children With the Autosomal Dominant Alzheimer Disease Presenilin 1 E280A Variant From a Colombian Cohort
48. Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study
49. Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred: A Cross-sectional Study
50. Psychosocial Determinants of COVID-19 Vaccination Intention Among White, Black, and Hispanic Adults in the US.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.